Si riporta di seguito la produzione scientifica di Sifact aggiornata al 12 Marzo 2018 (solo le riviste censite da PubMed).

Anno 2018

  1. Badiani B, Chiumente M, Messori A. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs. Eur J Obstet Gynecol Reprod Biol. 2018 Mar;222:84-88. doi: 10.1016/j.ejogrb.2018.01.020.
  2. Damuzzo V, Russi A, Chiumente M, Masini C, Rebesco B, Gregis F, Nozza S,Pigozzo J, Chiarion-Sileni V, Palozzo AC. Optimization of resources by drug management: A multicentred web-administered study on the use of ipilimumab in Italy. J Oncol Pharm Pract. 2018 Jan 1:1078155218755867. doi:10.1177/1078155218755867.
  3. Busa G, Burlina A, Damuzzo V, Chiumente M, Palozzo AC. Comorbidity, Polytherapy, and Drug Interactions in a Neurological Context: An Example of a Multidisciplinary Approach to Promote the Rational Use of Drugs. J Pharm Pract. 2018 Feb;31(1):58-65. doi: 10.1177/0897190017699138.

Anno 2017

  1. Chiumente M, Messori A. Rituximab biosimilar in rheumatoid arthritis: an enhanced-evidence assessment to evaluate equivalence with the originator based on network meta-analysis. Ther Adv Musculoskelet Dis. 2017 Oct;9(10):271-273. doi:10.1177/1759720X17721151.
  2. Chiumente M, Mengato D, Messori A. Rituximab biosimilar evaluated by network meta-analysis. Haematologica. 2017 Dec;102(12):e497-e498. doi:10.3324/haematol.2017.175042.
  3. Chiumente M, De Rosa M, Messori A, Proli EM. Burden of uterine fibroids in Italy: epidemiology, treatment outcomes, and consumption of health care resources in more than 5,000 women. Clinicoecon Outcomes Res. 2017 Aug 29;9:525-535. doi:10.2147/CEOR.S139335.
  4. Trippoli S, Chiumente M, Messori A. Promoting the use of Markovian simulation  models to study outcomes of thrombectomy after acute ischemic stroke. J Cardiovasc Med (Hagerstown). 2017 Oct;18(10):777-779. doi:10.2459/JCM.0000000000000532.
  5. Russi A, Damuzzo V, Chiumente M, Pigozzo J, Cesca M, Chiarion-Sileni V, Palozzo AC. Ipilimumab in real-world clinical practice: efficacy and safety data from a multicenter observational study. J Chemother. 2017 Aug;29(4):245-251. doi:10.1080/1120009X.2017.1311444.
  6. Gutiérrez-Ibarluzea I, Chiumente M, Dauben HP. The Life Cycle of Health Technologies. Challenges and Ways Forward. Front Pharmacol. 2017 Jan 24;8:14. doi: 10.3389/fphar.2017.00014.
  7. Mueller D, Gutiérrez-Ibarluzea I, Schuller T, Chiumente M, Ahn J, Pichon-Riviere A, García-Martí S, Grainger D, Cobbs E, Marchetti M. CAPACITY BUILDING IN AGENCIES FOR EFFICIENT AND EFFECTIVE HEALTH TECHNOLOGY ASSESSMENT. Int J Technol Assess Health Care. 2016 Jan;32(4):292-299.

Anno 2016 

  1. Mengato D, Messori A. Pricing of innovative drugs: correlation between incremental cost and survival gain in four countries. Ther Adv Med Oncol. 2016;Jul;8(4):309-11. doi: 10.1177/1758834016644465. Epub 2016 May 16.
  2. Palozzo AC, Messori A. Interventions of pharmaceutical disinvestment in the Italian national health system. Pharmacoeconomics  2016;34:419-420.
  3. Russi A, Serena M, Palozzo AC. Il prezzo dei farmaci oncologici va correlato al costo di sviluppo e produzione o al valore economico dell’efficacia clinica? Recenti Prog Med 2016; 107: 1-5 

Anno 2015

  1. Trippoli S, Chiumente M, Messori A. Differences in effectiveness among devices for endovascular thrombectomy in patients with acute ischemic stroke. J Stroke 2016;18(2):230-2.
  2. Messori A, De Rosa M, Fadda V, Pani L. Effectiveness and cost effectiveness of bevacizumab in metastatic colorectal cancer. J Clin Oncol. 2015;33(32):3838-9.
  3. Messori A, De Rosa M, Pani L. Alternative pricing strategies for cancer drugs. JAMA. 2015;313(8):857.
  4. De Rosa M, Messori A. The safety of bevacizumab vs ranibizumab in non-randomized studies. Int Ophthalmol 2015;35(2):157-8.

Progetti in corso

Aggiungi commento

Codice di sicurezza